Table 1. Efficacy of rucaparib by RECIST for the 71 patients by i.v. and oral rucaparib and by BRCA mutation status and tumour type.
| RECIST Response by patient no. (%) | All patients n=71 | The i.v. cohorts n=44 | BRCA1 ovaryn=16 | BRCA2 ovary n=10 | BRCA1 breast n=9 | BRCA2 breast n=9 | Oral cohorts n=27a | BRCA1 ovary n=16 | BRCA2 ovary n=3 | BRCA1 breast n=4 | BRCA2 breast n=1 | Oral cohorts continuous dosing n=17 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Objective response | 5 (7) | 1 (2) | 1 (6) | 0 (0) | 0 (0) | 0 (0) | 4 (15) | 3 (19) | 1 (33) | 0 (0) | 0 (0) | 3 (18) |
| Complete response | 1 (1) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (4) | 1 (6) | 0 (0) | 0 (0) | 0 (0) | 1 (6) |
| Partial response | 4 (6) | 1 (2) | 1 (6) | 0 (0) | 0 (0) | 0 (0) | 3 (11) | 2 (13) | 1 (33) | 0 (0) | 0 (0) | 2 (12) |
| Stable disease ⩾12 weeks | 35 (49) | 18 (41) | 4 (25) | 6 (60) | 4 (44) | 4 (44) | 17 (63) | 12 (75) | 2 (67) | 0 (0) | 1 (100) | 10 (59) |
| Progressive disease | 28 (39) | 22 (50) | 10 (63) | 3 (30) | 5 (56) | 4 (44) | 6 (22) | 1 (6) | 0 (0) | 4 (100) | 0 (0) | 4 (23) |
Abbreviations: CBR=clinical benefit rate; i.v.=intravenous; RECIST=Response Evaluation Criteria in Solid Tumours.
a
Includes data from three high-grade serous ovarian cancer patients who were unknown BRCA or BRCA wild type.